Diabetes protects against prostate cancer
ATLANTA, GEORGIA. The possible protective effect of diabetes against prostate cancer has been investigated once more, this time in a prospective study. Earlier studies have shown a reduction in risk of 10 to 40 per cent, and some suggest that diabetes is protective only several years after diagnosis. Researchers from the American Cancer Society used data on a group of 72,670 men from the Cancer Prevention Study II Nutrition Cohort. Information on diabetes and prostate cancer was gathered in 1982, 1992, 1997, 1999 and 2001. Prostate cancer was diagnosed in 5,318 men (7.3 per cent), who tended to be older and with a higher BMI.

The researchers found that overall; diabetes reduced the risk of prostate cancer by 33 per cent once age, race, education and prostate-specific antigen testing were taken into account. However, risk was significantly increased (by 23 per cent) in the first three years after diabetes diagnosis, compared with non- diabetic men, and only began to be protective after four years. The protective effect remained consistent when stage or grade of prostate cancer at diagnosis was examined. These results are consistent with the hypothesis that diabetes is associated with reduced risk of prostate cancer but only several years after diagnosis of diabetes, say the authors. The protective effect may be due to the reduced insulin levels found in men who have been diabetic for some time, as prostate cancer has been linked to high circulating levels of insulin.

The findings in the present study are consistent with results from a Health Professionals Follow-up Study, which also found an increased risk following diagnosis of diabetes and a protective effect after several years. In this study, prostate cancer risk was lowest 10 years after diabetes diagnosis, a reduction of 46 per cent. On the other hand, a recent case-control study within the US Physicians’ Health Study found a reduction in risk of 36 per cent, but with no link to the time since diabetes diagnosis.
Rodriguez, C et al. Diabetes and Risk of Prostate Cancer in a Prospective Cohort of US Men. American Journal of Epidemiology, Vol. 161, January 2005, pp. 147-152

Fish oils help prevent prostate cancer
BETHESDA, MARYLAND. Alpha-linolenic acid (ALA) is a major component of flax seed oil and has been associated with significant cardiovascular benefits. Some studies, however, have shown that a high intake of ALA is associated with an increased risk of prostate cancer. A prestigious team of researchers from the National Cancer Institute, the Harvard Medical School, the Harvard School of Public Health, and the Karolinska Institutet in Stockholm has just released the results of a study aimed at settling the controversy as to whether or not ALA is detrimental when it comes to prostate cancer. The researchers also determined the effect of other fatty acids, including fish oils, on prostate cancer risk.

The study involved 47,866 male American health professionals who were followed over a 14-year period beginning in 1986. The participants completed detailed food frequency questionnaires in 1986, 1990 and 1994. By the year 2000, 2965 new cases of prostate cancer had been reported with 448 of these being advanced (metastasized) or fatal. The overall incidence of new prostate cancer detected over the 14- year period was 0.5% per year.

The researchers found no correlation between ALA intake and overall prostate cancer risk, but did observe a strong association between a high ALA intake and the risk of advanced prostate cancer. Men with a high ALA intake (greater than 0.58% of energy or about 1.3 grams/day) were twice as likely to develop advanced prostate cancer as were men with a lower intake (less than 0.37% of energy or about 0.8 grams/day) even after adjusting for all other known variables that could affect the risk. The risk was slightly higher for ALA from non-animal sources than for ALA from meat and dairy sources. There was a trend for red meat, mayonnaise and salad dressings to be associated with a higher risk. The intake of two other abundant fatty acids, linoleic acid and arachidonic acid, was not related to prostate cancer risk.

The team of researchers found a protective effect associated with a high intake of fish oils - eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Men with a daily intake of more than 0.214% of daily energy (about 470 mg/day) were 11% less likely to develop prostate cancer than were men with an intake less than 0.057% of energy (about 125 mg/day). The beneficial effect of EPA plus DHA was particularly pronounced in regard to the incidence of advanced prostate cancer. Fish oil supplements were slightly less effective than fish oils from fatty fish perhaps indicating that vitamin D and vitamin A are necessary to obtain the maximum benefit.
Leitzmann, MF, et al. Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer. American Journal of Clinical Nutrition, Vol. 80, July 2004, pp. 204-16

Selenium and prostate cancer risk
BOSTON, MASSACHUSETTS. At least five major clinical trials have concluded that higher levels of selenium (in blood or toenail clippings) are associated with a sharply reduced risk of prostate cancer. The Nutritional Prevention of Cancer (NPC) trial found that supplementing with 200 micrograms/day of selenium cuts prostate cancer risk in half. Researchers at the Harvard Medical School now weigh in with another study confirming the beneficial effects of selenium. Their study involved 22,000 healthy, male physicians who were enrolled in the study in 1982 and had blood samples taken at that time. Sufficient samples to analyze for selenium content and PSA level were available for 586 men diagnosed with prostate cancer as well as for 577 controls matched for age and smoking status.

After 13 years of follow-up the researchers concluded that study participants with a plasma selenium level of 0.12-0.19 ppm had a 50% lower incidence of advanced prostate cancer than did men with a level of 0.06-0.09 ppm. The correlation was only apparent in men with a PSA level of more than 4 ng/mL and was particularly strong for those with a baseline (1982) PSA level greater than 10 ng/mL. For these men a high selenium level corresponded to a 70% decrease in the risk of advanced prostate cancer. The researchers also observed a trend for a lower incidence of localized prostate cancer with high selenium levels, but this trend was not statistically significant. They conclude that selenium is perhaps not too effective in preventing the initiation of prostate cancer, but that it is highly effective in slowing down tumor progression. They believe that selenium acts by selectively killing off cells whose DNA has been extensively damaged, by inhibiting cellular proliferation, and by its role as a key component of glutathione peroxidase, which protects cells from peroxide damage.
Li, H, et al. A prospective study of plasma selenium levels and prostate cancer risk. Journal of the National Cancer Institute, Vol. 96, May 5, 2004, pp. 696-703
Taylor, PR, et al. Science peels the onion of selenium effects on prostate carcinogenesis. Journal of the National Cancer Institute, Vol. 96, May 5, 2004, pp. 645-47 (editorial)

Editor's comment: The evidence is now indeed overwhelming that selenium helps protect against prostate cancer. While this study concluded that the protection mainly involves slowing down tumor progression, other studies have shown that selenium also helps prevent initiation of the cancer. Thus daily supplementation with 200 micrograms of selenium should be an integral part of all supplementation programs for men.

Testosterone and Alzheimer's disease
BETHESDA, MARYLAND. Researchers at the National Institute of Aging have found an association between the level of circulating free testosterone and the development of Alzheimer's disease (AD). Their study involved 574 men who joined the Baltimore Longitudinal Study of Aging since 1958 at ages between 32 and 87 years. The men had their total testosterone and sex hormone binding globulin (SHBG) measured at baseline and several times thereafter during an average 19-year follow-up period. The researchers found that a low free testosterone index (FTI) was associated with an increased risk of AD both at baseline and at the last measurement before the actual diagnosis of AD. FTI is equal to total serum testosterone level divided by SHBG level. Neither total testosterone nor SHBG levels, on their own, were associated with AD risk. Patients diagnosed with AD were approximately 7 years older than men not diagnosed with AD and also tended to be leaner (lower body mass index). Age and smoking were associated with increased risk, whereas education, BMI, diabetes, and hormone supplementation were associated with a reduced risk. After adjusting for all other variables the researchers concluded that each 10-unit increase in FTI corresponds to a 26% reduction in the risk of AD. They urge large-scale clinical trials to see if supplementation with testosterone might reduce the risk of Alzheimer's disease.
Moffat, SD, et al. Free testosterone and risk for Alzheimer disease in older men. Neurology, Vol. 62, January 2004, pp. 188-93
Henderson, VW and Hogervorst, E. Testosterone and Alzheimer's disease: Is it men's turn now? Neurology, Vol. 62, January 2004, pp. 170-71

Editor's comment: Testosterone supplementation should be approached with great caution and only done with the cooperation of a physician as it may increase the risk of prostate cancer.

Cancer trends in the USA
ATLANTA, GEORGIA. The annual report on the status of cancer in the United States has just been released. The report is a joint effort of the American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries. Overall cancer incidence rates were essentially stable between 1995 and 2000, but may be increasing slightly if allowing for reporting delays. Overall cancer death rates have remained steady from 1998 to 2000. More than half of all cancer diagnoses and deaths involve lung cancer, breast cancer, prostate cancer or colorectal cancer (cancer of the colon or rectum).

Lung cancer
Lung cancer incidence and mortality have been declining among men since 1991, but have increased among women. This is no doubt due to the fact that smoking control programs have been far more effective among men than among women. The average annual death rate from lung cancer was 56.8 per 100,000 for men and 40.7 for women (1996-2000). Lung cancer rates were lowest in Utah, the state with the lowest adult prevalence of smoking (13%) and the highest in Kentucky, the state with the highest adult smoking prevalence (31%).

Breast cancer
The incidence of female breast cancer has increased continually since 1986 particularly among white women. Death rates, however, have decreased steadily since the early 1990s possibly due to the more extensive use of mammography screenings. The average annual death rate from breast cancer (1996- 2000) was 27.7/100,000 with slightly higher rates observed among black women.

Prostate cancer
The incidence of prostate cancer has increased by 2.3% per year since 1994 and more recently by 3.0% per year among white men and by 2.3% per year among black men. Death rates, on the other hand, have been steadily declining and now stand at 32.9/100,000 (30.2 among white men and 73.0 among black men). Some experts argue that the increased use of PSA testing is responsible for the decline in mortality; however, the subject of screening for cancers is a highly controversial one. Dr. M.J. Quinn of the UK National Cancer Intelligence Centre points out that the use of the prostate specific antigen (PSA) test for screening purposes is not recommended by the US Preventive Services Task Force or in the European Code Against Cancer. He is clearly opposed to the use of PSA testing for screening purposes and points out that it may lead to unnecessary biopsies and dangerous treatments without any proven reduction in mortality.

Cancer of the colon and rectum
The incidence of colorectal cancer has stabilized since 1995 for both men and women and death rates have declined. Overall mortality rate for the period 1996-2000 was 21.2 per 100,000, but was particularly high among black men at 34.6/100,000.

The report concludes that overall cancer incidence and death rates began to stabilize in the mid to late 1990s, but have lately shown signs of increasing again.
Weir, Hannah K, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. Journal of the National Cancer Institute, Vol. 95, September 3, 2003, pp. 1276-99 Quinn, MJ. Cancer trends in the United States – A view from Europe. Journal of the National Cancer Institute, Vol. 95, September 3, 2003, pp. 1258-61

Selenium absorption by prostate tissue
BRISBANE, AUSTRALIA. There is considerable evidence that selenium may be protective against prostate cancer and there are currently several large clinical trials underway to determine definitively if selenium supplementation decreases the incidence of prostate cancer. Selenium is an important constituent of the body's naturally produced antioxidant, glutathione peroxidase, and its cancer preventive effect may be associated with increased glutathione levels.

If selenium proves to be cancer preventive it is clearly important to know whether selenium levels as measured in a blood sample correlates with actual selenium levels in prostate tissue. Researchers at the University of Queensland recently set out to answer this question. Their clinical trial involved 51 men who had been scheduled for transurethral resection for prostate enlargement. The men were randomly assigned to serve as controls or to receive selenium yeast tablets daily for one month prior to surgery. The tablets provided a total of 200 micrograms/day of selenium. Blood samples were taken at the beginning of the 30-day trial and on the day of surgery and the selenium content of red blood cells was compared to the selenium content of prostate tissue removed during surgery.

The researchers found that the red blood cell level of selenium had increased from 173 ng/mL to 209 ng/mL in the supplemented group with no significant change among controls. The selenium level in prostate tissue from supplemented men was significantly higher than among controls (241 ng/g versus 196 ng/g). The researchers conclude that selenium supplementation is effective in raising selenium levels in both prostate tissue and red blood cells, but conclude that selenium values from blood testing do not correlate with values obtained from testing of prostate tissue.
Gianduzzo, TRJ, et al. Prostatic and peripheral blood selenium levels after oral supplementation. Journal of Urology, Vol. 170, September 2003, pp. 870-73

Several studies have found a clear association between the western lifestyle and an increased risk of prostate cancer. A high intake of fat, meat and dairy products has been found to be particularly detrimental. Consuming fried or charcoal-grilled red meat has been clearly associated with increased risk. A high intake of alpha-linolenic acid and calcium from dairy products has both been associated with higher risk. A Swedish study found that men who consumed 600 mg/day of calcium from dairy products had a 32% greater risk than those consuming 150 mg/day or less.

Smoking, degree of physical activity, and alcohol consumption have not been associated with an increased risk and neither has vasectomy.

Soybean products (soy milk or tofu) have been found to have a preventive effect as has a high intake of tomato products, lycopene, selenium, and vitamin E. Supplementation with selenium reduced risk by 66% in one study while vitamin E supplementation lowered it by 40%. A large study involving 32,400 men is currently underway to confirm the benefits of vitamin-E and selenium supplementation. Results are expected by 2013.
Gronberg, Henrik. Prostate cancer epidemiology. The Lancet, Vol. 361, March 8, 2003, pp. 859-64

Prostate cancer and antioxidants
BALTIMORE, MARYLAND. There is growing evidence that certain micronutrients, more specifically antioxidants, may help prevent some forms of cancer. Selenium, for example, has been found highly effective in preventing prostate cancer. Researchers at the Johns Hopkins School of Public Health now report that gamma-tocopherol, the form of vitamin-E found in most foods, is also effective in preventing prostate cancer. Their study involved over 20,000 male residents of Washington County, Maryland who had donated blood in 1974 and 1989. A total of 324 men had developed prostate cancer by 1996. These men were each matched with two healthy controls in regard to age, race, and date of blood donation. Comparing the blood levels of micronutrients in cases and controls found no significant differences in concentrations of alpha-carotene, beta-carotene, total carotene, beta-cryptoxanthin, lutein, lycopene, retinol, and ascorbic acid (vitamin-C). There was, however, a difference in gamma-tocopherol levels between cases and controls with controls having significantly lower levels. For the men who donated blood in 1989 it was observed that men with the highest gamma-tocopherol levels had an almost 5 times lower incidence of prostate cancer than did those with the lowest levels. There was also some evidence that higher circulating levels of retinyl palmitate (formed from vitamin-A and stored in the liver) were protective against prostate cancer. The researchers conclude that gamma-tocopherol may help protect against prostate cancer, but note that lycopene did not appear to have any protective effect.
Huang, Han-Yao, et al. Prospective study of antioxidant micronutrients in the blood and the risk of developing prostate cancer. American Journal of Epidemiology, Vol. 157, February 15, 2003, pp. 335- 44

PC-SPES reborn?
LOS ANGELES, CALIFORNIA. A team of University of California (San Diego) researchers recently reported that PC-SPES, a much touted herbal remedy for prostate cancer, had been found to be heavily contaminated and had been taken off the market. Nevertheless, researchers at the UCLA Center for Human Nutrition in Los Angeles now report that they have found PC-SPES to be highly effective in preventing the initiation and progression of colon cancer. They evaluated PC-SPES in vitro using three different colon cancer cell lines. They found that the herbal compound caused a 95 per cent inhibition of cell proliferation in all three lines. In contrast, estradiol did not stop cell proliferation at all. Thus it is unlikely that the observed effect of PC-SPES is due to possible contamination with diethylstilbestrol, another estrogenic compound. The researchers also evaluated PC-SPES (250 mg/kg/day) in laboratory mice genetically engineered to develop multiple tumours in the gastrointestinal tract within a few weeks after birth. They found that mice treated 5 times a week for 10 weeks with PC-SPES developed 58 per cent less tumours than did control mice. They conclude that the components of PC-SPES, either independently or in combination, act to produce a drastic reduction in tumour initiation and progression in the gastrointestinal tract.
Huerta, Sergio, et al. PC-SPES inhibits colon cancer growth in vitro and in vivo. Cancer Research, Vol. 62, September 15, 2002, pp. 5204-09

Tomato sauce and prostate cancer
CHICAGO, ILLINOIS. Several studies have observed that tomatoes and tomato products, especially tomato sauce, have a protective effect against prostate cancer. Researchers at the University of Illinois now report that tomato sauce is also effective in slowing down and perhaps even reversing existing prostate cancer. Their study involved 32 patients with prostate cancer who were scheduled to undergo a radical prostatectomy. The participants underwent a baseline examination to determine their lycopene levels, their PSA (prostate specific antigen) level, and the level of oxidative damage to their DNA (in leukocytes). They were then fed a pasta dish with tomato sauce (3/4 of a cup of commercial spaghetti sauce) once a day for three weeks. The additional daily lycopene intake from the sauce was 30 mg.
At the end of the three-week period lycopene levels in the blood plasma had doubled and lycopene levels in prostate tissue had tripled. The average PSA level had declined from 10.9 ng/mL to 8.7 ng/mL – a drop of 17.5 per cent. The DNA damage indicator in leukocytes dropped by 21.4 per cent after the intervention. The DNA damage level in actual prostate tissue (removed during surgery) was found to be 28.3 per cent lower in the tomato sauce group than in a reference group of seven prostate cancer patients who had not consumed the tomato sauce diet. The researchers conclude that their study "suggests a role for tomato sauce and possibly for lycopene in the prevention and treatment of prostate cancer."
Chen, Longwen, et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce- based entrees as a whole-food intervention. Journal of the National Cancer Institute, Vol. 93, December 19, 2001, pp. 1872-79

Selenium prevents prostate cancer
STANFORD, CALIFORNIA. Several large studies have shown that men with low blood (plasma) levels of selenium have a significantly increased risk of prostate cancer. Now medical researchers at Stanford University and the Johns Hopkins University School of Medicine weigh in with another report that clearly shows the protective effect of selenium. Their study involved 52 men diagnosed with prostate cancer and 96 age-matched controls with no detectable prostate disease. The men had an average age of 69 years and were all enrolled in the Baltimore Longitudinal Study of Aging. Plasma levels of selenium measured in blood samples taken four to five years prior to the diagnosis of prostate cancer were compared for cancer patients and controls. The researchers found that men with selenium levels below 10.7 micrograms/dL had a four to five times higher incidence of prostate cancer than did men with levels above 10.7 micrograms/dL. They also noted a significant decline in selenium levels with age.
The researchers believe that much of the beneficial effect of selenium is due to its vital role in maintaining adequate levels of the body's main antioxidant, glutathione peroxidase. They conclude that selenium supplementation may reduce the risk of prostate cancer and that supplementation may be particularly important for older men. NOTE: The recommended daily intake of selenium is 55 micrograms with an upper safe limit of 400 micrograms/day. However, most supplementation studies have used 200 micrograms/day.
Brooks, James D., et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. Journal of Urology, Vol. 166, December 2001, pp. 2034-38

Prostate cancer and lycopene
DETROIT, MICHIGAN. Epidemiological studies have shown that a high intake of tomatoes markedly reduces the risk of prostate cancer. It is believed that this beneficial effect is due to lycopene, the most common carotenoid in tomatoes. A team of researchers from Wayne State University, McGill University, University of Maryland, and the University of Hawaii has just concluded a clinical trial aimed at evaluating the benefits of lycopene supplementation in prostate cancer patients. The study included 26 men with clinically localized prostate cancer who were scheduled to undergo radical prostatectomy (removal of the prostate gland). The men were randomized into a control group and an intervention group. The intervention group received one 15-mg lycopene capsule with breakfast and dinner for three weeks prior to surgery. Blood samples were taken before the start of supplementation and three weeks later just before surgery. The removed tumors and surrounding tissue were examined by pathologists.
The researchers conclude that lycopene supplementation lowers PSA levels; they observed an average 18 per cent decrease in the lycopene group as compared to a 14 per cent increase in the control group. The level of the tumor suppressing protein Cx43 in the malignant part of the tumor was found to be substantially higher in the lycopene group. It was also apparent that tumors tended to be smaller and more sharply defined (less encroachment into surrounding healthy tissue) in the lycopene group. No adverse effects of the lycopene supplementation were reported by the patients or their physicians. The researchers conclude that lycopene is likely to be beneficial for both prevention and treatment of prostate cancer, but urge larger trials to confirm this.
Kucuk, Omer, et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiology, Biomarkers & Prevention, Vol. 10, August 2001, pp. 861-68 [72 references]

Sun exposure prevents prostate cancer
STAFFORDSHIRE, UNITED KINGDOM. British researchers have confirmed that exposure to sunlight helps prevent prostate cancer. Their study involved 210 men diagnosed with prostate cancer and 155 men with an enlarged prostate, but no prostate cancer (controls). The men were interviewed in order to estimate their lifetime sun exposure. Men with the lowest exposure were found to have a three times greater incidence of prostate cancer than did men with a high lifetime exposure. Sunburns in childhood were found to be particularly protective with men having had one or more childhood sunburns being six times less likely to develop prostate cancer than men who had not experienced childhood sunburns.
A history of regular foreign holidays, presumably in sunnier climes, also had a protective effect with men having had such holidays having a 60 per cent lower risk of prostate cancer. Regular sun bathing was also found to be protective. The risk of prostate cancer was not associated with skin type, hair colour or eye colour, and the associations with sun exposure were not affected by including occupation, vasectomy or dietary factors in the analysis.
The researchers are not sure why sun exposure is protective, but speculate that vitamin D and parathyroid hormone may somehow be involved. Editor's Note: Excessive sun exposure has been linked to an increased risk of certain non-melanoma skin cancers. These cancers, however, are rarely fatal whereas prostate cancer often is. So on balance, cultivating a healthy suntan is still a good idea.
Luscombe, Christopher J., et al. Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. The Lancet, Vol. 358, August 25, 2001, pp. 641-42 (research letter)

Fish consumption helps prevent prostate cancer
STOCKHOLM, SWEDEN. Several studies have shown an inverse relationship between blood levels of fish oils (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) and the risk of prostate cancer. A study just completed by medical researchers at the Karolinska Institute confirms this association.
The Swedish study involved 3136 pairs of male twins born between 1886 and 1925. The participants completed food frequency questionnaires in 1961 and 1967 and were then followed up for 30 years. By December 31, 1997 the researchers had recorded 466 diagnoses of prostate cancer (340 fatal ones). The average age of diagnosis was 76.7 years. After adjusting for other known risk factors the researchers conclude that men who never eat fish have a two- to three-fold higher risk of prostate cancer than do men who eat moderate to high amounts. The researchers emphasize that only fatty fish such as salmon, herring and mackerel, which contain high amounts of omega-3 fatty acids (EPA and DHA), would be expected to be beneficial.
Terry, Paul, et al. Fatty fish consumption and risk of prostate cancer. The Lancet, Vol. 357, June 2, 2001, pp. 1764-66 (research letter)

Lycopene and cancer
TORONTO, CANADA. Lycopene is a carotenoid found in tomatoes, tomato products, and in other fruits. It is a powerful antioxidant with a singlet-oxygen quenching capacity 10 times greater than that of vitamin E. It is the most abundant carotenoid in human plasma and is highly concentrated in the adrenal glands, testes, prostate, and breast tissue. Several studies have found an inverse correlation between serum and tissue levels of lycopene and the risk of breast and prostate cancers. Other studies have linked a high intake of tomatoes to a 50 per cent reduction in cancer mortality among elderly Americans. One study found that men who consumed 10 or more servings of tomato products per week reduced their risk of prostate cancer by 35 per cent. A more recent study found that supplementation with a tomato extract significantly lowered the level of prostate-specific antigen (PSA) in patients with prostate cancer. High tissue (adipose) levels of lycopene have also been found to be protective against heart attacks. No published studies have shown any adverse effects of high lycopene levels or a high intake of tomato products. It has been hypothesized that lycopene prevents cancer and heart disease by protecting lipids, lipoproteins (especially low-density lipoprotein), proteins, and DNA. There is also evidence that lycopene counteracts the proliferation of cancer cells induced by insulin-like growth factors.
Agarwal, Sanjiv and Rao, AV. Tomato lycopene and its role in human health and chronic diseases. Canadian Medical Association Journal, Vol. 163, September 19, 2000, pp. 739-44 [70 references]

Eat your broccoli and avoid prostate cancer
SEATTLE, WASHINGTON. There is abundant evidence that a high intake of fruits and vegetables is protective against many types of cancer. Researchers at the Fred Hutchinson Cancer Research Center now report that the intake of vegetables, but not fruits, is significantly associated with prostate cancer risk. Their study involved 628 men from the Seattle area between the ages of 40 and 64 years who had been diagnosed with prostate cancer between January 1 and December 31, 1996. An age-matched sample of 602 men without prostate cancer served as the control group. All participants were interviewed and completed a 99-item food frequency questionnaire which included 12 fruit items and 21 vegetable items. The participants were asked to estimate their intake of the foods (ranging from "never or less than once per month" to "2+ per day") over the 3-5 years preceding the date of diagnosis or date of interview (for controls).

The intake of fruit did not significantly affect prostate cancer risk. However, men who consumed 28 or more servings of vegetables per week were found to have a 35 per cent lower risk than men who consumed fewer than 14 servings per week. When limiting the analysis to cruciferous vegetables only the protective effect was found to be even more pronounced. Men who ate three or more servings of cruciferous vegetables (broccoli, cauliflower, brussel sprouts, cabbage) per week had a 41 per cent lower risk of developing prostate cancer than did men who ate less than one serving a week. A high intake of lutein plus zeaxanthin (2000 micrograms/day or more) was associated with a 32 per cent decrease in risk, but this association was not statistically significant. The researchers found no correlation between the intake of tomato products or lycopene and prostate cancer risk.
Cohen, Jennifer, et al. Fruit and vegetable intakes and prostate cancer risk. Journal of the National Cancer Institute, Vol. 92, January 5, 2000, pp. 61- 68

Beta-carotene and cancer
BOSTON, MASSACHUSETTS. Numerous epidemiological studies have concluded that high intakes of fruits and vegetables are associated with lower risks of cancer. It was originally thought that beta- carotene was the protective component, but six large-scale clinical trials have failed to confirm any cancer-protective effects. Two of the trials involving heavy smokers showed a significant 18 per cent increase in lung cancer among the smokers who took beta-carotene. One very large trial involving 22,071 American physicians showed no benefits and no harm from 12 years of supplementation with 50 mg of synthetic beta-carotene every second day.
Researchers at the Harvard Medical School have just released the results of a major study aimed at evaluating the effects of beta-carotene supplementation among women. The study involved almost 40,000 healthy female health professionals (aged 45 years or older). The women were randomized into two groups with one group receiving 50 mg of synthetic beta-carotene on alternate days and the other group receiving a placebo. The 2.1-year supplementation phase of the study was followed by a two-year observation period. At the end of the four years 747 cases of cancer and 218 cases of cardiovascular incidents (heart attack, stroke, and death) had occurred among the women. There were no significant differences in the incidence of cancer, cardiovascular events or death from all causes in the two groups. This also held true when just the smokers among the women were considered.
The researchers conclude that beta-carotene supplementation is neither harmful nor beneficial to people at average risk for cancer except in the case of prostate cancer. The Physicians' Health Study found that men who supplemented with 50 mg of beta-carotene every second day for 12 years had a significantly lower incidence of prostate cancer.
Lee, I. Min, et al. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. Journal of the National Cancer Institute, Vol. 91, December 15, 1999, pp. 2102-06

Fish oils help prevent prostate cancer
AUCKLAND, NEW ZEALAND. Medical researchers in New Zealand provide convincing evidence that an increased consumption of fish oils helps reduce the risk of developing prostate cancer. Their study involved 317 men who had been diagnosed with prostate cancer during 1996-97 and 480 age-matched controls. Blood samples were obtained from all participants and the erythrocyte (red blood cell) phosphatidylcholine fraction of the plasma was analyzed for EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), the two main components of fish oils.

Evaluation of the collected data showed a clear correlation between blood level of EPA and DHA and the presence of prostate cancer. Study participants with levels in the highest quartile were found to have a 40 per cent lower incidence than participants with levels in the lowest quartile. This relationship held true even when adjusted for age, height, use of NSAIDs (non- steroidal anti-inflammatory drugs), socio-economic status, and estimated intake of lycopene and polyunsaturated fats.

The researchers also found that men with low socio-economic status, a low intake of lycopene, and non-regular use of NSAIDs were more likely to develop prostate cancer. They did not, however, find any correlation between self- reported intake of EPA and DHA indicating that food frequency questionnaires are not an accurate method for estimating fish oil intake. The researchers speculate that fish oils may prevent the progression of prostate cancer by inhibiting the biosynthesis of eicosanoids from arachidonic acid.
Norrish, A.E., et al. Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. British Journal of Cancer, Vol. 81, No. 7, December 1999, pp. 1238-42

Diet is vital in cancer prevention
SACRAMENTO, CALIFORNIA. It is estimated that 35% of all cancers are directly associated with the typical American diet; another 30% is directly related to smoking. A high fat intake is associated with cancer of the colon, breast, prostate, rectum, and endometrium. These cancers are also associated with obesity as are cancers of the kidney, cervix, and thyroid. Alcohol consumption is implicated in cancers of the breast, rectum, mouth, and esophagus. The consumption of charred, smoked, salted, and pickled foods is associated with cancer of the stomach and esophagus. On the other hand, an increased fiber intake has been found to protect against colon cancer - presumably because it speeds up elimination of waste through the bowels. An increased consumption of fruit and vegetables has been found to have a protective effect against lung, colon, breast, prostate, bladder, mouth, cervix, and stomach cancer. The Amercian Cancer Society has recommended that efforts be made to change the typical American diet so that it contains no more than 30% fat (% of total calories) - in 1985 the average diet contained 36%. It also recommends 5 or more servings of fruit and vegetables per day (1986 average was 2.5) and 6 or more servings a day of breads, cereals, and legumes (1986 average was 3). The Society would like to see these dietary changes implemented by the year 2000 and estimates that 166,000 cancer deaths and 315,000 new cases of cancer could be avoided every year if they were.
Bal, Dileep G. and Foerster, Susan B. Dietary strategies for cancer prevention. Cancer (Supplement), Vol. 72, No. 3, August 1, 1993, pp. 1005- 10
Byers, Tim. Dietary trends in the United States. Cancer (Supplement), Vol. 72, No. 3, August 1, 1993, pp. 1015-18

Vitamin A may prevent prostate cancer
HOUSTON, TEXAS. Vitamin A (retinol) and its biologically active metabolite, retinoic acid, are known to be useful in the prevention and treatment of certain cancers such as acute promyelocyte leukemia. Now researchers at the Baylor College of Medicine report that vitamin A may also play a role in the prevention and treatment of prostate cancer. The researchers analyzed prostate tissue from patients with stage 3+ prostate cancer, tissue from patients with benign prostate hyperplasia (enlarged prostate), and normal tissue. They made several interesting observations:

• All tissues tested contained retinol and retinoic acid in various concentrations. The retinol concentration in tissue from enlarged prostates was 2.5 times higher than in normal tissue or tissue from cancer patients. Tissue from cancer patients contained near normal levels of retinol, but only barely detectable levels of retinoic acid.
• The prostate contains enzymes which enables it to convert retinol supplied in the diet to the biologically active retinoic acid.

Selenium protects against cancer
TUCSON, ARIZONA. Several studies have shown that the incidence and mortality from many cancers are higher in geographical areas where the selenium content of forage crops is low. Now an impressive group of researchers from more than half a dozen universities in the United States report that selenium supplementation helps prevent cancer. The Nutritional Prevention of Cancer Study Group found that cancer mortality was cut in half in a group of patients who supplemented with selenium. The double-blind, randomized, placebo- controlled cancer prevention trial involved 1312 patients aged 18 to 80 years (75 per cent males) who had previously been diagnosed with basal or squamous cell carcinomas of the skin. The purpose of the trial, started in 1983, was to test the hypothesis that selenium supplementation helps prevent skin cancer. Half the patients were randomized to receive 200 micrograms/day of selenium supplied as a 0.5 gram high-selenium brewer's yeast tablet (Nutrition 21, LaJolla, CA); the other half received a placebo. Patients were treated for a mean of 4.5 years and had a mean total follow-up period of 6.4 years. At the end of the study the researchers concluded that selenium supplementation does not prevent skin cancer. They did, however, find strong evidence that selenium supplementation is very effective in preventing other types of cancer. The overall mortality rate from cancer in the supplemented group was found to be only half of that in the placebo group. The reduction in mortality and incidence was particularly impressive in the case of cancers of the lung, prostate, colon, and rectum. The incidence and mortality rate from lung cancer was twice as high in the placebo group as in the selenium group. Supplement users developed only one third the number of prostate cancers as did the members of the placebo group and the incidence of colon and rectal cancer was similarly reduced in the supplement group. Unfortunately, there was not enough data to statistically evaluate the effect of selenium supplementation on the incidence of breast and ovarian cancers. The researchers were so impressed with the results of the trial that they decided to stop it early so that all patients could benefit from selenium supplementation. They believe selenium combats cancer by inhibiting the late stage promotion and progression of tumors. No toxic effects of selenium supplementation were observed.
Clark, Larry C., et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. Journal of the American Medical Association, Vol. 276, No. 24, December 25, 1996, pp. 1957-63
Colditz, Graham A. Selenium and cancer prevention - promising results indicate further trials required. Journal of the American Medical Association, Vol. 276, No. 24, December 25, 1996, pp. 1984-85 (editorial)

Beans and garden peas may reduce risk for prostate cancer
Leeds, England. Preliminary evidence has shown that eating baked beans and garden peas may reduce the risk for developing prostate cancer. A recent study interviewed 328 English-speaking men previously diagnosed with prostate cancer before the age of 75 years and 328 age-matched population controls. The purpose of the study was to investigate the association between diet and prostate cancer. Interviews included questions on basic demographic details, smoking, family history and food intake during the last five years. Main dietary concerns were fat intake (saturated, monounsaturated, or polyunsaturated fatty acids) and the intake of carotenes (beta-carotene and lycopene). Participants were also asked if they had taken vitamins or other supplements. The researchers found no statistically significant differences in the intake of fats or carotenes between the prostate cancer patients and controls. They do point out however, that total fat intake (in per cent of total energy intake) of both patients and controls was quite high (34-43 per cent) and that they can draw no conclusion as to what effect a low fat intake would have on the risk of developing prostate cancer.

Among foods and other nutrients examined, significant associations were observed for garlic (food only or food plus supplements), baked beans, vitamin B6 and garden peas. The association with garlic and vitamin B6 was later found to be statistically insignificant when adjusted for social class. Another recent study in England found that men who ate beans and peas more than once a week had a 37 per cent reduction in risk compared to men who ate these foods less often. The confirmed risks for prostate cancer include age, a family history of prostate cancer, social class and ethnic group/country of residence. A history of prostate cancer in fathers and brothers was associated with a two- to three-fold increased risk for the disease and manual workers were found to have a 63 per cent higher risk of prostate cancer than did non-manual workers. No correlation was found between risk and alcohol intake or smoking. Contrary to other recent studies, the researchers found no effect of increased lycopene intake. However, they point out that their estimate of lycopene intake was very crude and did not account for the wide differences in bioavailability of lycopene from different sources. The researchers also noted that the use of vitamin E supplements was considerably higher among controls, but no significant correlation with cancer rate was observed. The researchers conclude that there is, as yet, no clear correlation between diet and prostate cancer risk but that the effect of a high intake of vitamin B6 (pyridoxine), garlic, peas and beans warrants further investigation.
Key, T.J.A., et al. A case-control study of diet and prostate cancer. British Journal of Cancer, Vol. 76, No. 5, September 1997, pp. 678-87

Finasteride does not prevent prostate cancer
LOS ANGELES, CALIFORNIA. Finasteride (Proscar) is often prescribed for benign prostatic hyperplasia (enlarged prostate gland) and is effective in shrinking the gland and reducing the level of dihydrotestosterone (DHT) which is believed to be involved in the enlargement. It has recently been postulated that finasteride may prevent prostate cancer and a large trial is currently being conducted by the US National Cancer Institute to test this hypothesis. Now researchers at the University of Southern California present a study which shows that finasteride does not reduce the risk of prostate cancer in high risk men, but may in fact increase it. The study involved 52 men with PSA (prostate-specific antigen) levels over 4.0 nanogram/ml and negative biopsies for prostate cancer. The men were randomized to receive either 5 mg/day of finasteride (27 patients) or no medication (25 patients) for a 12-month period. At the end of the trial period prostate biopsies were again performed. Eight patients (30 per cent) of the men in the finasteride group were found to have developed prostate cancer (adenocarcinoma) as compared to one patient (4 per cent) in the control group. The researchers conclude that their study "raises serious questions about the probable efficacy of finasteride in preventing prostate cancer."
Cote, R.J., et al. The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. British Journal of Cancer, Vol. 78, No. 3, August 1998, pp. 413-18

Selenium intake and prostate cancer
BOSTON, MASSACHUSETTS. The connection between a low selenium content in the soil and regional cancer mortality rates has been known for almost 30 years. Later research has confirmed an association between low blood levels of selenium and the prevalence of colon, lung, and stomach cancers. More recently, a team of American researchers reported that men who supplemented with 200 micrograms of selenium daily had a three times lower risk of developing prostate cancer than did men in the placebo group. All the participants in this study lived in areas of the USA where the soil is selenium-deficient and the normal dietary intake is estimated to be about 90 micrograms/day. Another recent study investigated the association between advanced prostate cancer and toenail concentrations of selenium (an indicator of long term selenium intake). This study found that men with the highest toenail selenium concentrations had a three times lower risk of advanced prostate cancer than did men with the lowest concentrations. The researchers estimate that the daily median selenium intake among men with the lowest toenail concentrations was about 86 micrograms as compared to about 159 micrograms for men with the highest toenail concentrations. Dr. Edward Giovannucci, MD of the Harvard Medical School points out that selenium intakes in the UK have been falling over several decades and now may be as low as 30- 40 micrograms/day. During the same period the incidence and mortality from prostate cancer have increased substantially in England and Wales. Dr. Giovannucci suggests that there may be a connection, but this has not as yet been proven. He concludes that "the evidence (of the benefits of selenium supplementation) available for prostate cancer seems to justify the further assessment of increasing the selenium intake in the population as a priority for public health."
Giovannucci, Edward. Selenium and risk of prostate cancer. The Lancet, Vol. 352, September 5, 1998, pp. 755-56 (commentary)

Lycopene and prostate cancer
BOSTON, MASSACHUSETTS. Several studies have shown that a high dietary intake of tomatoes and tomato-based products especially tomato sauce is associated with a lower risk of prostate cancer. It is assumed that the carotenoid lycopene is the component which is primarily responsible for the protective effect. Now researchers at the Harvard Medical School confirm the validity of this assumption. Their study involved over 22,000 male American physicians aged 40 to 84 years at the start of the study in 1982. The original purpose of the study was to investigate the effects of beta-carotene supplementation (50 mg every other day). However, the availability of stored blood samples made it possible to investigate the effects of other carotenoids as well. By 1995 578 men had developed prostate cancer. These were matched with 1294 cancer-free men according to age and smoking status. Analysis of the blood levels of carotenoids and vitamin E showed that men with the highest lycopene levels and no beta-carotene supplementation had a 41 per cent lower risk of prostate cancer than did men with the lowest levels. No risk reduction associated with lycopene levels was observed in physicians who received beta- carotene supplementation. However, beta-carotene in itself also appeared to be protective with men assigned to supplementation having a 37.3 per cent lower risk than men with low lycopene levels assigned to placebos. Men with high vitamin E (alpha-tocopherol) levels were found to have a lower incidence of aggressive prostate cancer. The researchers conclude that increased consumption of tomato products might reduce prostate cancer risk.
Gann, Peter H., et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Research, Vol. 59, March 15, 1999, pp. 1225-30

DHEA protects against prostate cancer
We do not usually report information based on animal experiments; however, the finding that DHEA can prevent or even reverse prostate cancer in laboratory rats seemed important enough to make an exception.

CHICAGO, ILLINOIS Prostate cancer is the second most common cause of cancer death in Western male populations. It is estimated that about 18 per cent of American men will develop prostate cancer during their lifetime. Some researchers believe that many more have the beginnings of prostate cancer, but die from other causes before the cancer becomes invasive and fatal. Research has shown that the hormone DHEA (dehydroepiandrosterone) inhibits the growth of both human and rat prostate cancer cells in vitro (in test tubes). Now a team of researchers from the National Cancer Institute, the New York University School of Medicine, and the ITT Research Institute reports that DHEA confers significant protection against prostate cancer progression when given to laboratory rats as part of their diet. Their experiment involved rats which were given carcinogenic chemicals to induce precancerous lesions in the prostate. One group of rats had 1000 or 2000 mg of DHEA added to each kilogram of feed starting one week before inducing the cancer. Other groups had 2000 mg of DHEA added per kilogram of diet one week before induction, 20 weeks after induction or 40 weeks after induction. The rats received the DHEA until the experiment was concluded 13 months after cancer induction. Control rats received no DHEA. The researchers found a very significant decrease in the progression to full prostate cancer among the rats given DHEA in their diets. This effect was evident whether the DHEA was given one week before or 20 or 40 weeks after cancer induction. They conclude that DHEA or a suitable derivative may be effective in preventing the development and progression of prostate cancer in humans, but caution that more work is required to ensure the DHEA's hormonal effects (conversion to testosterone and estrogenic activity) are not detrimental.
Rao, K.V.N., et al. Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Research, Vol. 59, No. 13, July 1, 1999, pp. 3084-89

Testosterone supplementation and prostate cancer
KIRKLAND, WASHINGTON. Conventional medicine wisdom has it that high levels of male sex hormones (androgens) are associated with an increased risk of prostate cancer and a more rapid tumour growth. This has led to the use of chemical or physical castration in an attempt to reduce natural androgen production and thereby deprive the tumour of the androgen it supposedly requires to keep growing. Unfortunately, the effect of castration is often temporary and subsequent tumours tend to be more virulent than the original one.

Now Dr. Richmond Prehn, MD of the University of Washington challenges the assumption that high androgen levels are a risk factor for prostate cancer. Dr. Prehn points out that androgen levels decline with age whereas prostate cancer incidence rises sharply. He suggests that declining androgen levels may not only lead to benign prostate hyperplasia (BPH), but may also be the initiator of uncontrolled cell growth which may ultimately lead to cancer. He further suggests that "androgen supplementation beginning early in the middle years might, among other possible benefits, largely prevent prostate cancer." Dr. Prehn cautions that androgen supplementation may be contra-indicated in older men who already have the seeds of prostate cancer. He also suggests that an alternating regimen of androgen deprivation and androgen supplementation should be evaluated as a therapy for prostate cancer.
Prehn, Richmond T. On the prevention and therapy of prostate cancer by androgen administration. Cancer Research, Vol. 59, September 1, 1999, pp. 4161-64